TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04144257
Drug: [C-11]Methylreboxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET radiopharmaceutical. Subjects will undergo \[C-11\]MRB-PET (norepinephrine transporter binding).
Study: NCT00745004
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule matching over-encapsulated experimental drug. 1 capsule OD, dose titrated up to a maximum of 2 capsules tds or down to a minimum of 1 capsule alternate days. For 5 weeks.
Study: NCT04112316
Drug: Liothyronine
Normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liothyronine (L-triiodothyronine or LT3) in the 5 mcg tablet dose formulation. Minimum LT3 dose was 2.5 mcg three times daily and the maximum LT3 dose was 12.5 mcg three times daily.
Study: NCT02534181
Drug: Caloric Management Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strategy based on reduction of nutritional intake and electrolyte replacement.
Study: NCT04270526
Drug: Standard protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradetrussor treatment with 50 mL 1% lidocaine + 50ml of 0.9% normal saline
Study: NCT00055393
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 subjects received Placebo.
Study: NCT00003403
Drug: GPX-100
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02473250
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bipolar depressed patients will be treated with fluoxetine in combination with a mood stabilizer (valproate).
Study: NCT03954366
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of 20mg oral rosuvastatin on Day 1 and Day 19 only.
Study: NCT00904943
Drug: Topamax® Capsules, 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 25 mg Capsules
Study: NCT06781073
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combined with chemotherapy period, 400mg, day1, administered intravenously before chemotherapy ,weekly, for 18 weeks; Maintenance period, 400mg, every two weeks until disease progression or intolerable toxicity , maximum duration is 60 weeks .
Study: NCT00688987
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will receive in random order daily (split) dosing of hydrocortisone: a low dose of 15 mg (10 in AM, 5 in PM); a medium dose of 25 mg (15 in AM, 10 in PM) and high dose of 40 mg (30 in AM, 10 in PM) for 4 months.
Study: NCT04342858
Drug: Fluoride Varnish with tricalcium phosphate
Normalized name: tricalcium phosphate
DrugBank: Calcium citrate (DB11093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clinpro white varnishTM, 3M ESPE, St Paul, MN, USA
Study: NCT01539616
Drug: ZYH7
Normalized name: I do not have enough information to determine the full generic name for the drug abbreviation 'ZYH7'. Drug abbreviations can vary and may not have a standardized full generic name. Without more context about the specific drug or clinical trial data, I cannot provide the full generic name. I apologize that I cannot give you a more definitive answer.
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZYH7 4mg given once orally in the morning before breakfast, for 8 weeks.
Study: NCT01539616
Drug: ZYH7
Normalized name: I do not have enough information to determine the full generic name for the drug abbreviation 'ZYH7'. Drug abbreviations can vary and may not have a standardized full generic name. Without more context about the specific drug or clinical trial data, I cannot provide the full generic name. I apologize that I cannot give you a more definitive answer.
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZYH7 8 mg given once orally in the morning before breakfast, for 8 weeks.
Study: NCT01539616
Drug: ZYH7
Normalized name: I do not have enough information to determine the full generic name for the drug abbreviation 'ZYH7'. Drug abbreviations can vary and may not have a standardized full generic name. Without more context about the specific drug or clinical trial data, I cannot provide the full generic name. I apologize that I cannot give you a more definitive answer.
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZYH7 16 mg given once orally in the morning before breakfast, for 8 weeks.
Study: NCT03039699
Drug: Ergoferon
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03039699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00422942
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-25mg po weekly
Study: NCT03715127
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of placebo (100% mannitol)
Study: NCT00149227
Drug: Non-ARB
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: 'Non-ARB' was defined conventional anti-hypertensive treatment except for ACEIs and ARBs
Study: NCT00544674
Drug: PR104
Normalized name: PR104
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered at a dose of 1100 mg/m\^2 by intravenous infusion over 1 hour and repeated every three weeks
Study: NCT00129220
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, oral tablets, twice daily (morning and evening), for 3 weeks
Study: NCT02895074
Drug: Proparacaine hydrochloride
Normalized name: Proparacaine Hydrochloride
DrugBank: Proparacaine (DB00807)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical anesthesia with proparacaine hydrochloride (0.5%) was applied.
Study: NCT03626454
Drug: Norepinephrine Bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 'Norepinephrine Bitartarte' bolus of 6 µg/mL for 30 seconds immediately after intrathecal injection
Study: NCT03626454
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: an infusion of 6 µg/mL norepinephrine that was started at 6 µg/kg/h immediately after intrathecal injection
Study: NCT03626454
Drug: Normal Saline Flush, 0.9% Injectable Solution
Normalized name: Normal Saline Flush, 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml normal saline in syringe for bolus for 30 seconds immediately after intrathecal injection
Study: NCT03626454
Drug: Normal Saline 0.9% Infusion Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml syringe with normal saline infuse at a rate 1ml/kg/h immediately after intrathecal injection
Study: NCT03117010
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose dexamethasone 20 mg PO or IV
Study: NCT00749866
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised 80mg twice daily
Study: NCT02814916
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin was administered orally every 8 hours.
Study: NCT03804840
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00834977
Drug: Lotrel® 10 mg-20 mg capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 10-20 mg
Study: NCT01112826
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine 650 mg/m2 twice every day for 1 year.
Study: NCT00312156
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00876902
Drug: Viaspan® and saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of a volume equivalent to active study drug will be prepared for administration to the control group to help maintain the blind. Those patients that experience an intraoperative blood loss of \>10 units, will receive an additional 1 mg/kg IV infusion of placebo equivalent at the end of the transplant surgery.
Study: NCT01494753
Drug: T2345
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One drop at 8.00pm.
Study: NCT01494753
Drug: Prostaglandin
Normalized name: Prostaglandin
DrugBank: Prostaglandin G2 (DB03866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop at 8.00pm.
Study: NCT04492514
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion
Study: NCT02155166
Drug: ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 hour prior to the LNG-IUS insertion
Study: NCT03927703
Drug: SB206 12%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically once daily
Study: NCT00307658
Drug: Intravenous immunoglobulins (human immunoglobulins G)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00303719
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be given in a two hour infusion, total dose 50 mg/kg on day -6.
Study: NCT02600715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo to B\&O suppository
Study: NCT00656136
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive placebo once daily
Study: NCT00656136
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive afatinib tablets once daily, and can reduce dose for adverse event management. Afatinib is given once daily, continuously until disease progression or unacceptable toxicity.
Study: NCT01782027
Drug: 3H-cholesterol bound to albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: up to 100 uCi of \[3H\]-cholesterol (containing approximately 0.2 mg of cholesterol) mixed with a solution containing human serum albumin will be administered as an intravenous bolus injection
Study: NCT00006359
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupron: 22.5mg IM injection q 12 wks x 2 OR Zoladex: 10.8 mg subQ injection q 12 wks x 2
Study: NCT00006359
Drug: antiandrogen
Normalized name: Antiandrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: flutamide 250 mg PO tid for 4 wks OR casodex 50 mg PO daily for 4 wks
Study: NCT00887822
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to bevacizumab on Day 1 of every 3-week cycle
Study: NCT00887822
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2 orally twice daily on Days 1-14 of every 3-week cycle
Study: NCT02063802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months
Study: NCT01540721
Drug: Marketed paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: marketed formulation
Study: NCT01540721
Drug: Experimental paracetamol formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental formulation
Study: NCT00719706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01110603
Drug: MK-4827
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, orally, once daily, on Days 1 and 3 of each 21- or 28-day Cycle, at the assigned dose level, starting at 40 mg per dose.
Study: NCT01110603
Drug: liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion, 30 mg/m2, once, on Day 3 of each 28-day cycle
Study: NCT01452685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
Study: NCT04276493
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT02083406
Drug: 800mg OZ439 prototype formulation 1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02083406
Drug: 800mg OZ439 prototype formulation 2
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02083406
Drug: 800mg OZ439 prototype formulation 3
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01917799
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.4 mL/day of the Enoxaparin
Study: NCT03633461
Drug: OC-02 (simpinicline) nasal spray
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC-02 (simpinicline) nasal spray, 11.1 mg/ml
Study: NCT03633461
Drug: Placebo (vehicle) nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle) nasal spray
Study: NCT03682471
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 10 mM sodium phosphate, 0.9% \[w/v\] sodium chloride in water for subcutaneous injection.
Study: NCT03585829
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: at a substitutive dosage
Study: NCT03585829
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: at a substitutive dosage
Study: NCT02502994
Drug: GEN0101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02138929
Drug: LDE 225
Normalized name: LANCET,STERILANCE LDE 2 DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction Phase Starting Dose: 400 mg by mouth daily in a 28 day cycle.~Expansion Phase Starting Dose: Maximum tolerated dose from Induction Phase.
Study: NCT02898662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Placebo administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is Placebo 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
Study: NCT00386035
Drug: Delayed ART
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants follow a drug conservation (DC) regimen in which ART is stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count is at least 350 cells/mm3, and then are followed by episodic ART based on CD4 cell count.
Study: NCT00386035
Drug: Continuous ART
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 participants follow a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count.
Study: NCT03907072
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered saline solution
Study: NCT04586920
Drug: LY3509754
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04586920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01973205
Drug: Acetaminophen 250 mg and Aspirin 250 mg
Normalized name: Acetaminophen 250 mg and aspirin 250 mg and caffeine 65 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg
Study: NCT01973205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets
Study: NCT04026113
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT00687596
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to placebo received 2 placebo tablets (identical in appearance to the TAC 101 tablets) administered PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) in a regimen identical to that for TAC 101.
Study: NCT04230759
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive chemotherapy cycles as followed:~Mitomycin-C 12 mg/m², day 1 (maximum single dose 20 mg) 5-FU: 1000 mg/m² per day, continuous i.v. infusion, on day 1-4 and 29-32
Study: NCT03970330
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily placebo pill, taken orally
Study: NCT02903771
Drug: Part A: Dose Escalation of Cantrixil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cantrixil will be administered via the intraperitoneal route only. The dose of study drug that each participant will receive will depend on how far the study has progressed when the participant enrols. There are 9 potential doses of Cantrixil, they are 0.06, 0.12, 0.24 (starting dose), 0.6, 1.25, 2.5, 5, 10, or 20 mg/kg. The dose each participant receives will remain the same during the study, unless it needs to be reduced for safety reasons. The dose will not be increased.~Each participant will receive the study drug once a week during the first two cycles; each cycle is 21-days (three weeks); the MTD will be determined during Cycle 1 only. If after two cycles of monotherapy, the patient tolerates Cantrixil adequately, they may continue to receive Cantrixil once a week and will also begin combination chemotherapy for another 6 cycles. Participants will receive no more than 8 cycles of study drug.
Study: NCT02903771
Drug: Part B: Expansion Cohort of Cantrixil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once the MTD has been established, an expansion cohort will be recruited at the MTD. An additional 12 patients will be recruited in this cohort on top of those recruited in Part A at the MTD. These patients will be subjected to the same intervention described in Part A with 2 cycles of monotherapy followed by up to 6 cycles of combination therapy.
Study: NCT00733096
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two transforaminal epidural saline injections, two weeks apart
Study: NCT04073290
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
Study: NCT04055220
Drug: Treatment by Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment for 13 cycles (12 months) maximum.~During each cycle, patient will take once a day, during 21 days, followed by 7 days without placebo treatment :~* 3 placebo tablets (3 weeks out of 4 weeks) in patients ≥ 16 years old and patients \< 16 years old with BSA ≥ 1.70m²;~* 2 placebo tablets (3 weeks out of 4 weeks) in patients \< 16 years old with 1.30m² ≤ BSA \< 1.70m²;
Study: NCT01883596
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.
Study: NCT04994860
Drug: BIA 5-1058
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral BIA 5-1058 (Zamicastat) 100 mg tablets
Study: NCT04506073
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be identical to the investigational product but will not contain mesenchymal stem cells (MSCs).
Study: NCT03569241
Drug: androgen deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH-agonist (+ anti-androgen) or antagonist for a duration of 6 months
Study: NCT00497458
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: testosterone 40 or 80 mg once a day
Study: NCT00683527
Drug: Elemental iron
Normalized name: Elemental Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron in the dose of 3-4 mg/kg/day (of elemental iron) PO once daily mixed with expressed breast milk from 14 days of life till the end of study period
Study: NCT03672721
Drug: IA Carbo+ Radiation
Normalized name: Carbo animalis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of intraarterial carboplatin + radiation in dose escalation
Study: NCT01426100
Drug: CKD-828 40/2.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination of Telmisartan 40mg and S-Amlodipine 2.5mg
Study: NCT01426100
Drug: CKD-828 40/5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination of Telmisartan 40mg and S-Amlidioine 5mg
Study: NCT00107198
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00107198
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02625610
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction Phase: Leucovorin was administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
Study: NCT02625610
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction Phase: Capecitabine was administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase every 3 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
Study: NCT02625610
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction Phase: Leucovorin will be administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.
Study: NCT02625610
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction Phase: Capecitabine will be administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.
Study: NCT03654053
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken once nightly at bed time.
Study: NCT03654053
Drug: Simvastatin 40mg
Normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40mg taken once nightly at bed time.
Study: NCT00699582
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
Study: NCT02538705
Drug: Neovasculgen
Approvals — FDA: no, EMA: no, PMDA: no